Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center Department of Psychiatry and Behavioral Science, New York, New York, USA
Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center Department of Psychiatry and Behavioral Science, New York, New York, USA.
BMJ Support Palliat Care. 2022 Sep;12(3):339-346. doi: 10.1136/bmjspcare-2020-002457. Epub 2020 Aug 27.
Depression and vitamin D deficiency are common in patients with lung cancer and have prognostic implications in cancer settings. However, their relationship and concomitant survival implications have not been evaluated in patients with metastatic lung cancer specifically. We hypothesised that vitamin D deficiency would be associated with depression and inferior cancer-related survival in patients receiving therapies for stage IV lung cancer.
This was a cross-sectional analysis of vitamin D, depression and lung cancer characteristics. Vitamin D levels were stratified by level (no deficiency ≥30 units, mild deficiency 20 to 29 units and moderate-to-severe <20 units). Depression was measured by the Hospital Anxiety and Depression Scale-Depression (HADS-D). Survival estimations were made using Cox proportional hazard model and Kaplan-Meier analyses.
Vitamin D deficiency was evident in almost half of the sample (n=98) and was associated with significant depression (HADS-D ≥8) (χ=4.35, p<0.001) even when controlling for age, sex and inflammation (β=-0.21, p=0.03). Vitamin D deficiency and depression were associated with worse survival and showed evidence of an interaction effect (HR 1.5, p=0.04).
Vitamin D deficiency is associated with depression in patients with metastatic lung cancer. Depression modulates the survival implications of vitamin D deficiency in this population. The role of vitamin D deficiency in cancer-related depression warrants further investigation since both are amenable to treatment. Psychological and nutritional prognostic considerations may help inform treatment paradigms that enhance quality of life and survival.
在肺癌患者中,抑郁和维生素 D 缺乏很常见,并且在癌症环境中具有预后意义。然而,它们在转移性肺癌患者中的关系及其伴随的生存意义尚未得到专门评估。我们假设,在接受 IV 期肺癌治疗的患者中,维生素 D 缺乏与抑郁以及癌症相关的生存质量下降有关。
这是一项关于维生素 D、抑郁和肺癌特征的横断面分析。根据水平将维生素 D 水平分层(无缺乏症≥30 单位,轻度缺乏症 20 至 29 单位,中度至重度缺乏症<20 单位)。使用医院焦虑和抑郁量表-抑郁(HADS-D)来衡量抑郁程度。使用 Cox 比例风险模型和 Kaplan-Meier 分析进行生存估计。
几乎有一半的样本(n=98)存在维生素 D 缺乏症,并且与明显的抑郁(HADS-D≥8)相关(χ=4.35,p<0.001),即使在控制年龄、性别和炎症时也是如此(β=-0.21,p=0.03)。维生素 D 缺乏症和抑郁与生存质量下降有关,并且显示出存在交互作用的证据(HR 1.5,p=0.04)。
在转移性肺癌患者中,维生素 D 缺乏与抑郁有关。在该人群中,抑郁调节了维生素 D 缺乏的生存意义。维生素 D 缺乏在癌症相关抑郁中的作用值得进一步研究,因为两者都可以通过治疗来改善。心理和营养预后考虑因素可能有助于告知治疗方案,以提高生活质量和生存。